December 11-12, 2019 | Alexandria, VA
World Congress invites you to the Pharmaceutical Drug Pricing Strategies and Copay Summits where experts will share their solutions for critical issues.
Join your peers to learn from 35 speakers and enjoy 5 hours of networking at The Westin, Alexandria, VA. Drug Channels readers save $200 off the standard rate when you use promo code DC200 and register by November 8th.* To register your team, contact World Congress at 800-767-9499.
The price of prescription drugs and affordability of treatments is at the center of the health care debate. These Summits address the critical juncture of price and affordability, by showcasing strategies, innovations, and best practices across the bio/pharmaceutical industry to share how to be a part of the solution.
Given the recent news headlines, Senate finance hearings, and the introduction of drug pricing transparency laws, drug pricing is under the national spotlight. Hear both perspectives at the Pharmaceutical Drug Pricing Strategies Summit which brings pricing and reimbursement leaders together to discuss the future of federal and state pricing requirements, transparency regulations, and strategic drug pricing models.
The 2nd Annual Copay Summit convenes multiple stakeholders together, from manufacturers, payers, states, government, advocacy, and foundational groups, to examine regulations and innovations around the use of Copay and Coupon programs, and Copay Accumulator and Maximizers in an evolving health care landscape.
The Summits’ in-depth sessions will help you attain solutions for issues your organization faces in drug pricing and copay strategies.
- Develop strategic drug pricing models to meet federal and state pricing requirements and ensure transparency
- Examine the changes regarding copay accumulator adjustments, state copay legislation, and compliant assistance programs
- Explore multi-stakeholder insights from manufacturers, and insurers, on the future of drug price transparency and patient affordability
- Mike Mason, Vice President, Lilly Diabetes, Senior Vice President, Connected Care and Insulins Eli Lilly and Company; he recently testified before the U.S. House of Representatives
- Robert Popovian, Vice President, US Government Relations, Pfizer; he has published and presented extensively on the impact of biopharmaceuticals and health policies on health care costs and clinical outcomes
- Peter Pitts, President of the Center for Medicine in the Public Interest; he is a former member of the United States Senior Executive Service and was FDA’s Associate Commissioner for External Relations
*Cannot be combined with other offers or prior registrations.
The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.
No comments:
Post a Comment